webinar register page

Future of Cell & Gene Therapy for Life Sciences
Cell and gene therapy provide an almost limitless source of new ideas. These treatments are personalised and have the potential to be useful for a variety of illnesses. The COVID-19 pandemic highlighted how the pharmaceutical sector can work together to achieve a major goal like vaccine development in a short amount of time. While cell and gene therapies (CGTs) have the potential to revolutionise oncology and other critical diseases therapy, the industry must first overcome enormous cultural and systemic constraints.
To introduce desired sequence alterations, current gene-editing technologies use nuclease-based systems to cut DNA strands and trigger DNA repair mechanisms. Multiple waves of next-generation editing technologies are queued up on the heels of these efforts to increase specificity, precision, efficiency, and applicability to other types of disease, even though these technologies are only now beginning to be tested clinically. The breakthroughs of base editing and prime editing, for example, have made it possible to precisely alter genomic sequences in the absence of DNA breaks and without relying on the activity of endogenous DNA repair processes.
Leaning toward these technologies will result in future cell and gene therapy facilities that can pivot fast in a global health context where flexibility and efficiency are valued highly. The COVID-19 pandemic has revealed a concerning lack of readiness to move quickly from clinical vaccination testing to large-scale manufacturing.

The cell and gene therapy sector is booming, as it is with many new ecosystems, with thorough reviews of many diseases, formats, and technology. We may expect a more focused focus on R & D activities as this field evolves and is reinforced by even more scientific evidence, allowing these therapies to mature.
To provide more insight and detailed analysis into the future of this industry, Group Futurista is happy to present its “Future of Cell & Gene Therapy for Life Sciences”.
* Required information